Epigenetics in lung cancer diagnosis and therapy

Cancer and Metastasis Reviews

Volumn 34, Issue 2, 2015, Pages 229-241

  Mehta, Aditi ^a   Dobersch, Stephanie ^a   Romero Olmedo, Addi J ^a,b   Barreto, Guillermo ^a,c  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b UNIVERSIDAD AUTÓNOMA BENITO JUÁREZ DE OAXACA   (Mexico)

^c KAZAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

Chromatin; DNA methylation; Early diagnosis; Epigenetics; Histone modifications; Lung cancer; Metastasis; miRNA; Treatment

Indexed keywords

4 PHENYLBUTYRIC ACID; AZACITIDINE; DECITABINE; MICRORNA; ROMIDEPSIN; SODIUM; TRICHOSTATIN A; VALPROIC ACID; HISTONE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CHROMATIN STRUCTURE; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; FATALITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; PRIORITY JOURNAL; ANIMAL; GENETIC EPIGENESIS; GENETICS; LUNG NEOPLASMS; PROCEDURES;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; HISTONES; HUMANS; LUNG NEOPLASMS; MICRORNAS;

EID: 84938419882     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-015-9563-3     Document Type: Article

References (129)

1. Balgkouranidou, I., Liloglou, T., & Lianidou, E. S. (2013). Lung cancer epigenetics: emerging biomarkers. Biomarkers in Medicine, 7(1), 49–58.
2. Molina, J. R., et al. (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings, 83(5), 584–594.
3. Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008). Lung cancer. New England Journal of Medicine, 359(13), 1367–1380.
4. Hoffman, P. C., Mauer, A. M., & Vokes, E. E. (2000). Lung cancer. Lancet, 355(9202), 479–485.
5. Nemeth, A., & Langst, G. (2004). Chromatin higher order structure: opening up chromatin for transcription. Briefings in Functional Genomics & Proteomics, 2(4), 334–343.
6. Zhang, Y. (2011). Recent progress in the epigenetics and chromatin field. Cell Research, 21(3), 373–374.
7. Brzezianska, E., Dutkowska, A., & Antczak, A. (2013). The significance of epigenetic alterations in lung carcinogenesis. Molecular Biology Reports, 40(1), 309–325.
8. Ozturk, N., Singh, I., Mehta, A., Braun, T., & Barreto, G. HMGA proteins as modulators of chromatin structure during transcriptional activation. Frontiers in Cell and Developmental Biology.
9. Esteller, M. (2008). Epigenetics in cancer. New England Journal of Medicine, 358(11), 1148–1159.
10. Deaton, A. M., & Bird, A. (2011). CpG islands and the regulation of transcription. Genes and Development, 25(10), 1010–1022.
11. Cedar, H., & Bergman, Y. (2009). Linking DNA methylation and histone modification: patterns and paradigms. Nature Reviews Genetics, 10(5), 295–304.
12. Wang, Y., et al. (2004). Beyond the double helix: writing and reading the histone code. Novartis Foundation Symposium, 259, 3–17. discussion 17–21, 163–9.
13. Knudson, A. G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America, 68(4), 820–823.
14. Kim, H., et al. (2006). Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer, 107(5), 1042–1049.
15. Lin, R. K., et al. (2007). Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer, 55(2), 205–213.
16. Feinberg, A. P., & Vogelstein, B. (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 301(5895), 89–92.
17. Weber, M., et al. (2005). Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genetics, 37(8), 853–862.
18. Rauch, T. A., et al. (2008). High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 105(1), 252–257.
19. Lander, E. S., et al. (2001). Initial sequencing and analysis of the human genome. Nature, 409(6822), 860–921.
20. Gaudet, F., et al. (2003). Induction of tumors in mice by genomic hypomethylation. Science, 300(5618), 489–492.
21. Gupta, P. K., et al. (1997). High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination. Cancer Research, 57(6), 1188–1193.
22. Holt, D., et al. (1999). Interindividual variation in mitotic recombination. American Journal of Human Genetics, 65(5), 1423–1427.
23. Maloisel, L., & Rossignol, J. L. (1998). Suppression of crossing-over by DNA methylation in Ascobolus. Genes and Development, 12(9), 1381–1389.
24. Kim, M., et al. (2004). Dnmt1 deficiency leads to enhanced microsatellite instability in mouse embryonic stem cells. Nucleic Acids Research, 32(19), 5742–5749.
25. Beck, C. R., et al. (2011). LINE-1 elements in structural variation and disease. Annual Review of Genomics and Human Genetics, 12, 187–215.
26. Sargurupremraj, M., & Wjst, M. (2013). Transposable elements and their potential role in complex lung disorder. Respiratory Research, 14, 99.
27. Iskow, R. C., et al. (2010). Natural mutagenesis of human genomes by endogenous retrotransposons. Cell, 141(7), 1253–1261.
28. Dupuy, A. J., et al. (2005). Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature, 436(7048), 221–226.
29. Collier, L. S., et al. (2005). Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature, 436(7048), 272–276.
30. Xing, J., et al. (2009). Mobile elements create structural variation: analysis of a complete human genome. Genome Research, 19(9), 1516–1526.
31. Lujambio, A., et al. (2010). CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene, 29(48), 6390–6401.
32. Lin, S. H., et al. (2014). Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics, 15, 1079.
33. Thiery, J. P., et al. (2009). Epithelial-mesenchymal transitions in development and disease. Cell, 139(5), 871–890.
34. Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation, 119(6), 1420–1428.
35. Le Bras, G. F., Taubenslag, K. J., & Andl, C. D. (2012). The regulation of cell-cell adhesion during epithelial-mesenchymal transition, motility and tumor progression. Cell Adhesion & Migration, 6(4), 365–373.
36. Richardson, F., et al. (2012). The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Research, 32(2), 537–552.
37. Xiao, D., & He, J. (2010). Epithelial mesenchymal transition and lung cancer. Journal of Thoracic Disease, 2(3), 154–159.
38. Singh, A., & Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 29(34), 4741–4751.
39. Fu, J., et al. (2011). The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Research, 21(2), 275–289.
40. Yang, J., et al. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117(7), 927–939.
41. Tran, P. T., et al. (2012). Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genetics, 8(5), e1002650.
42. De Craene, B., & Berx, G. (2013). Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews Cancer, 13(2), 97–110.
43. Van’t Westeinde, S. C., & van Klaveren, R. J. (2011). Screening and early detection of lung cancer. Cancer Journal, 17(1), 3–10.
44. Mulshine, J. L. (2003). Screening for lung cancer: in pursuit of pre-metastatic disease. Nature Reviews Cancer, 3(1), 65–73.
45. Marshall, H. M., et al. (2013). Screening for lung cancer with low-dose computed tomography: a review of current status. Journal of Thoracic Disease, 5(Suppl 5), S524–S539.
46. Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63(1), 11–30.
47. Ahrendt, S. A., et al. (1999). Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. Journal of the National Cancer Institute, 91(4), 332–339.
48. Selamat, S. A., et al. (2011). DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One, 6(6), e21443.
49. Yanagawa, N., et al. (2003). Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Science, 94(7), 589–592.
50. Pulling, L. C., et al. (2003). Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Research, 63(16), 4842–4848.
51. Kim, J. S., et al. (2005). Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer, 104(9), 1825–1833.
52. Lin, Q., et al. (2009). RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. Journal of Cancer Research and Clinical Oncology, 135(12), 1675–1684.
53. Kneip, C., et al. (2011). SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. Journal of Thoracic Oncology, 6(10), 1632–1638.
54. Tsou, J. A., et al. (2007). Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Molecular Cancer, 6, 70.
55. Niklinska, W., et al. (2009). Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochemica et Cytobiologica, 47(2), 275–280.
56. Risse, E. K., et al. (1985). Sputum cytology by the Saccomanno method in diagnosing lung malignancy. Diagnostic Cytopathology, 1(4), 286–291.
57. Hubers, A. J., et al. (2014). Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis. Journal of Clinical Pathology, 67(8), 707–711.
58. Leng, S., et al. (2012). Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clinical Cancer Research, 18(12), 3387–3395.
59. Wang, Y. C., et al. (2003). Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. Journal of Clinical Investigation, 111(6), 887–895.
60. Liu, Y., et al. (2003). Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis, 24(12), 1897–1901.
61. Destro, A., et al. (2004). K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer, 44(1), 23–32.
62. Belinsky, S. A., et al. (2007). Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. British Journal of Cancer, 96(8), 1278–1283.
63. Cirincione, R., et al. (2006). Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case–control study. International Journal of Cancer, 118(5), 1248–1253.
64. Ammanagi, A. S., et al. (2012). Sputum cytology in suspected cases of carcinoma of lung (Sputum cytology a poor man’s bronchoscopy!). Lung India, 29(1), 19–23.
65. Hsu, H. S., et al. (2007). Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer, 110(9), 2019–2026.
66. Suga, Y., et al. (2008). Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer. Oncology Reports, 20(5), 1137–1142.
67. Bearzatto, A., et al. (2002). p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clinical Cancer Research, 8(12), 3782–3787.
68. Russo, A. L., et al. (2005). Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clinical Cancer Research, 11(7), 2466–2470.
69. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.
70. Boedeker, E., Friedel, G., & Walles, T. (2012). Sniffer dogs as part of a bimodal bionic research approach to develop a lung cancer screening. Interactive Cardiovascular and Thoracic Surgery, 14(5), 511–515.
71. Rattray, N. J., et al. (2014). Taking your breath away: metabolomics breathes life in to personalized medicine. Trends in Biotechnology, 32(10), 538–548.
72. Dent, A. G., Sutedja, T. G., & Zimmerman, P. V. (2013). Exhaled breath analysis for lung cancer. Journal of Thoracic Disease, 5(Suppl 5), S540–S550.
73. Xiao, P., et al. (2014). Methylation of P16 in exhaled breath condensate for diagnosis of non-small cell lung cancer. Lung Cancer, 83(1), 56–60.
74. Han, W., et al. (2009). Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients. Respiratory Research, 10, 86.
75. Filipowicz, W., Bhattacharyya, S. N., & Sonenberg, N. (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics, 9(2), 102–114.
76. Ebert, M. S., & Sharp, P. A. (2012). Roles for microRNAs in conferring robustness to biological processes. Cell, 149(3), 515–524.
77. Calin, G. A., et al. (2004). MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the National Academy of Sciences of the United States of America, 101(32), 11755–11760.
78. Lu, J., et al. (2005). MicroRNA expression profiles classify human cancers. Nature, 435(7043), 834–838.
79. Trang, P., et al. (2010). Regression of murine lung tumors by the let-7 microRNA. Oncogene, 29(11), 1580–1587.
80. Johnson, S. M., et al. (2005). RAS is regulated by the let-7 microRNA family. Cell, 120(5), 635–647.
81. Takamizawa, J., et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Research, 64(11), 3753–3756.
82. Hayashita, Y., et al. (2005). A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Research, 65(21), 9628–9632.
83. Donnem, T., et al. (2012). MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One, 7(1), e29671.
84. Boeri, M., et al. (2011). MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 108(9), 3713–3718.
85. Pritchard, C. C., Cheng, H. H., & Tewari, M. (2012). MicroRNA profiling: approaches and considerations. Nature Reviews Genetics, 13(5), 358–369.
86. Nair, V. S., Maeda, L. S., & Ioannidis, J. P. (2012). Clinical outcome prediction by microRNAs in human cancer: a systematic review. Journal of the National Cancer Institute, 104(7), 528–540.
87. Cagle, P. T., & Chirieac, L. R. (2012). Advances in treatment of lung cancer with targeted therapy. Archives of Pathology and Laboratory Medicine, 136(5), 504–509.
88. (2011) In The diagnosis and treatment of lung cancer (Update). Cardiff (UK).
89. Schuchert, M. J., et al. (2010). Sublobar resection for early-stage lung cancer. Seminars in Thoracic and Cardiovascular Surgery, 22(1), 22–31.
90. Sonke, J. J., & Belderbos, J. (2010). Adaptive radiotherapy for lung cancer. Seminars in Radiation Oncology, 20(2), 94–106.
91. Pfister, D. G., et al. (2004). American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. Journal of Clinical Oncology, 22(2), 330–353.
92. Simone, C. B., 2nd, et al. (2013). Stereotactic body radiation therapy for lung cancer. Chest, 143(6), 1784–1790.
93. Timmerman, R., et al. (2010). Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA, 303(11), 1070–1076.
94. Ma, P.C. (2012). Personalized targeted therapy in advanced non-small cell lung cancer. Cleveland Clinic Journal of Medicine, (79 Electronic Suppl 1), eS56–60.
95. Sandler, A., et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, 355(24), 2542–2550.
96. Davies, M. (2014). New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Management and Research, 6, 63–75.
97. Hatzimichael, E., & Crook, T. (2013). Cancer epigenetics: new therapies and new challenges. Journal of Drug Delivery, 2013, 529312.
98. Jones, P. A., & Baylin, S. B. (2007). The epigenomics of cancer. Cell, 128(4), 683–692.
99. Chuang, J. C., & Jones, P. A. (2007). Epigenetics and microRNAs. Pediatric Research, 61(5 Pt 2), 24R–29R.
100. Dawson, M. A., & Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell, 150(1), 12–27.
101. Keohane, C., Mesa, R., & Harrison, C. (2013). The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms. American Society of Clinical Oncology Educational Book, 301–305.
102. Liu, S. V., et al. (2013). Epigenetic therapy in lung cancer. Frontiers in Oncology, 3, 135.
103. Lyko, F., & Brown, R. (2005). DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. Journal of the National Cancer Institute, 97(20), 1498–1506.
104. Tang, M., et al. (2009). Potential of DNMT and its epigenetic regulation for lung cancer therapy. Current Genomics, 10(5), 336–352.
105. Christman, J. K. (2002). 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene, 21(35), 5483–5495.
106. Komashko, V. M., & Farnham, P. J. (2010). 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics, 5(3), 229–240.
107. Kim, H. J., & Bae, S. C. (2011). Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. American Journal of Translational Research, 3(2), 166–179.
108. Brazelle, W., et al. (2010). Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One, 5(12), e14335.
109. Tang, Y. A., et al. (2010). A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS One, 5(9), e12417.
110. Perrino, E., et al. (2008). New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorganic and Medicinal Chemistry Letters, 18(6), 1893–1897.
111. Tesei, A., et al. (2012). Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. Journal of Cellular Physiology, 227(10), 3389–3396.
112. Zhang, W., et al. (2009). Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. Journal of Thoracic Oncology, 4(2), 161–166.
113. Karthik, S., et al. (2014). Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomedicine and Pharmacotherapy, 68(3), 327–334.
114. Papeleu, P., et al. (2003). Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes. Journal of Hepatology, 39(3), 374–382.
115. Mukhopadhyay, N. K., et al. (2006). Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer. Annals of Thoracic Surgery, 81(3), 1034–1042.
116. Platta, C. S., et al. (2007). The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. Journal of Surgical Research, 142(2), 219–226.
117. Juergens, R.A., & Rudin, C.M. (2013). Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target. American Society of Clinical Oncology Educational Book.
118. Petta, V., et al. (2013). Histones and lung cancer: are the histone deacetylases a promising therapeutic target? Cancer Chemotherapy and Pharmacology, 72(5), 935–952.
119. Li, C. T., et al. (2011). Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells. Journal of Cellular Biochemistry, 112(10), 3044–3053.
120. Forde, P. M., Brahmer, J. R., & Kelly, R. J. (2014). New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer. Clinical Cancer Research, 20(9), 2244–2248.
121. Belinsky, S. A., et al. (2011). Combination therapy with Vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Research, 71(2), 454–462.
122. Noro, R., et al. (2007). PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. International Journal of Oncology, 31(5), 1157–1163.
123. Peipp, M., et al. (2002). A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Research, 62(10), 2848–2855.
124. Deng, X. K., Nesbit, L. A., & Morrow, K. J., Jr. (2003). Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system. Clinical and Diagnostic Laboratory Immunology, 10(4), 587–595.
125. Frenzel, A., Hust, M., & Schirrmann, T. (2013). Expression of recombinant antibodies. Frontiers in Immunology, 4, 217.
126. Wang, R., et al. (2013). Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone Skp. Frontiers in Cellular and Infection Microbiology, 3, 72.
127. Kumar, P., et al. (2008). T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell, 134(4), 577–586.
128. Xu, X., et al. (2012). Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 109(13), 4910–4915.
129. Oh, Y. K., & Park, T. G. (2009). siRNA delivery systems for cancer treatment. Advanced Drug Delivery Reviews, 61(10), 850–862.